Statin Use and In-hospital Mortality in Patients with COVID-19 and Coronary Heart Disease

Scientific Reports

Lan Shen¹  Ben He¹  Li Wang²  Jingjin Jin³  Ying Xiao³  Xiulan Liu³  Dong Liu³  Lin Qiu³  Yi Liu³  Dao Wen Wang⁴  Ning Zhou⁴  Hengye Huang⁵ 

[1] Department of Cardiology, Clinical Research Unit, Shanghai Chest Hospital, Shanghai Jiaotong University, 200030, Shanghai, China;Department of Geriatrics, School of Medicine, Shanghai Renji Hospital, Shanghai Jiaotong University, 200127, Shanghai, China;Department of Pharmacy, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, 1095 Jiefang Ave., 430030, Wuhan, China;Division of Cardiology, Department of Internal Medicine, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, 1095 Jiefang Ave, 430030, Wuhan, China;School of Public Health, School of Medicine, Shanghai Jiaotong University, 200025, Shanghai, China;

DOI  :  10.1038/s41598-021-02534-2

来源: Springer

【 摘 要 】

The worsening progress of coronavirus disease 2019 (COVID-19) is attributed to the proinflammatory state, leading to increased mortality. Statin works with its anti-inflammatory effects and may attenuate the worsening of COVID-19. COVID-19 patients were retrospectively enrolled from two academic hospitals in Wuhan, China, from 01/26/2020 to 03/26/2020. Adjusted in-hospital mortality was compared between the statin and the non-statin group by CHD status using multivariable Cox regression model after propensity score matching. Our study included 3133 COVID-19 patients (median age: 62y, female: 49.8%), and 404 (12.9%) received statin. Compared with the non-statin group, the statin group was older, more likely to have comorbidities but with a lower level of inflammatory markers. The Statin group also had a lower adjusted mortality risk (6.44% vs. 10.88%; adjusted hazard ratio [HR] 0.47; 95% CI, 0.29–0.77). Subgroup analysis of CHD patients showed a similar result. Propensity score matching showed an overall 87% (HR, 0.13; 95% CI, 0.05–0.36) lower risk of in-hospital mortality for statin users than nonusers. Such survival benefit of statin was obvious both among CHD and non-CHD patients (HR = 0.30 [0.09–0.98]; HR = 0.23 [0.1–0.49], respectively). Statin use was associated with reduced in-hospital mortality in COVID-19. The benefit of statin was both prominent among CHD and non-CHD patients. These findings may further reemphasize the continuation of statins in patients with CHD during the COVID-19 era.

【 授权许可】

CC BY